brain concussion News
-
BrainScope Honors Veterans Day and Supports U.S. Army Deployment of Traumatic Brain Injury (TBI) and Concussion Assessment Devices
BrainScope®, a medical neuro-technology company focused on concussion and mild traumatic brain injury (mTBI) assessment, announced today that it has fulfilled orders for over 170 BrainScope One handheld devices and over 7,500 individual patient headsets to U.S. Army bases across the world. U.S. Army medics and clinicians continue to receive the training necessary to support the assessment of ...
-
JAMA Highlights Success of BrainScope`s EEG-based Concussion Index As Reliable Indicator of Concussion
JAMA Network Open has published "Validation of a Machine Learning Brain Electrical Activity-Based Index to Aid in Diagnosing Concussion Among Athletes," a ground-breaking study on the accuracy of the BrainScope FDA-cleared biomarker, the Concussion Index, to indicate the likelihood and severity of concussive brain injury and to aid in evaluating an athlete's readiness to return to play. "What ...
-
BrainScope Receives $4.5 Million Department of Defense Contract to Add Ocular Assessment to Future Concussion Products
BrainScope today announced that it has been awarded a research contract by the United States Department of Defense (DOD) valued at $4.5 million to create and integrate ocular capabilities into its handheld, multi-parameter mild Traumatic Brain Injury (mTBI) and concussion products. BrainScope’s initial product in the market, BrainScope One, is the first FDA-cleared medical device to offer ...
-
BrainScope Launches Next-Gen Medical Device: First and only FDA-cleared system for true point-of-care assessment of both concussion and brain bleeds now includes Concussion Index
BrainScope today announced the availability of its third groundbreaking FDA-cleared algorithm on the BrainScope device. The Concussion Index is the first physiological marker of concussive injury that aids clinicians in the objective assessment of patients at baseline, point of injury, and through recovery. The Concussion Index adds to the suite of FDA cleared algorithms already available on the ...
-
BrainScope and Aon Secure IP-based Deal Funding Full Expansion of Commercial Activities and Pursuit of New Indications for BrainScope’s Next-Gen Medical Device Platform
Brain-assessment device innovator BrainScope, and Aon plc (NYSE: AON), a leading global professional services firm, today announced the completion of an intellectual property-based funding arrangement. The funding arrangement provides BrainScope with up to $35 million in capital to fund the full expansion of its commercial activities as well as to develop new clinical applications on its ...
-
BrainScope Completes Agreement with 18,000 Member Yankee Alliance
BrainScope today announced a new system-wide agreement with Yankee Alliance to make BrainScope’s innovative point-of-care neuro-technology system available to the 18,000 members, including over 5000 outpatient facilities and senior centers, in Yankee Alliance. BrainScope is the only FDA cleared medical device that aids in the objective triage of head injured patients for suspected mild ...
-
BrainScope Receives Prix Galien Award Nomination for Its Concussion and Traumatic Brain Injury Assessment Product
BrainScope today announced its second consecutive nomination for the 2018 Annual Prix Galien USA Awards for “Best Medical Technology" product. Its flagship BrainScope One product is a multi-modal, comprehensive, handheld capability to help clinicians objectively and rapidly assess and triage head injured patients directly at the point of care. BrainScope’s innovative technology ...
-
BrainScope Announces Publication Describing Proprietary Concussion Biomarker to Assess Potential Severity and Predict Prolonged Recovery
BrainScope®, a medical neuro-technology company focused on concussion and mild traumatic brain injury (mTBI) assessment, announced today that researchers have published preliminary results related to a multi-modal concussion assessment capability for potential severity and likelihood of prolonged recovery from concussions. Published in the peer-reviewed journal Computers in Biology and ...
-
BrainScope Completes Large-Scale Clinical Studies of Concussion in Universities, High Schools and Concussion Clinics
BrainScope®, a medical neuro-technology company focused on concussion and mild traumatic brain injury (mTBI) assessment, announced today that it had concluded both algorithm development and clinical validation studies in adolescent and young adult populations using its objective, EEG-based technology. The purpose of the studies was to create and validate an objective, personalized capability ...
-
Over 30% Reduction in Unnecessary Head CT Scans When Integrating FDA-Cleared BrainScope One
BrainScope announced today the publication of a study conducted by physicians at Washington University Barnes Jewish Medical Center in St. Louis in the peer-reviewed journal The American Journal of Emergency Medicine entitled “Reduction in unnecessary CT scans head-injury in the emergency department using an FDA cleared device." The study demonstrated that the FDA-cleared BrainScope One ...
-
BrainScope Wins BioHealth Capital Region 5th Annual Crab Trap Competition
BrainScope, a medical neurotechnology company that is a pioneer in the use of A.I. and machine learning in the creation of biomarkers of brain injuries and disease was selected from five finalists as the company with the most commercial potential at the 5th Annual BioHealth Capital Region Crab Trap Competition. The Bethesda, Maryland based company is helping hospital Emergency Departments (EDs) ...
-
BrainScope Advances its Commercial Adoption and Appoints Industry Veteran Susan Hertzberg as CEO
BrainScope announced today the appointment of Susan Hertzberg as Chief Executive Officer. This is the 4th equity-backed venture that Hertzberg will helm. She is a proven commercial stage leader with an impressive track record of bringing innovative products and services to market and profitably scaling and delivering exceptional market growth. In her new role, Hertzberg will drive the global ...
-
Iron Horse Dx wins Arizona Commerce Authority Innovation Challenge
The Arizona Commerce Authority announced Iron Horse Diagnostics a winner of the Fall 2014 Arizona Innovation Challenge. A panel of expert judges evaluated 154 applications from the Fall 2014 AIC submitted by companies based in Arizona, California, Colorado, New Mexico, Ohio, West Virginia and Virginia. The judges assessed each application on a set of criteria including technology potential, ...
By nVector
-
NFL & GE Announce Six Final Winners of $10 Million Head Health Challenge
Innovations are advancing the understanding and diagnosis of mild traumatic brain injury Breakthrough ideas include: point-of-care blood test to rapidly detect the presence of mild and moderate brain trauma; biomarkers that indicate how the brain reacts following a traumatic brain injury (TBI) and a method to identify which brain areas become disconnected after injury GE (NYSE: GE) and the ...
-
BrainScope Surpasses Primary Endpoints in Multi-Year Department of Defense-Funded Validation Study for New Concussion Assessment Capability
BrainScope announced today that it has successfully completed a nearly five year, $9.9 million U.S. Department of Defense research contract supporting the development and validation of an objective marker of the presence and severity of concussion. In a large blinded validation study, the system demonstrated its ability to help clinicians assess concussion at the time of injury, reflect severity ...
-
BrainScope Receives FDA Clearance for Multi-Modal, Multi-Parameter Concussion Assessment
BrainScope®, a medical neuro-technology company focused on concussion and mild traumatic brain injury (mTBI) assessment, announced today that it has received FDA clearance to include additional language in its product’s Indications for Use (IFU), adding key terminology related to “multi-modal, multi-parameter assessment" of “concussion" and “mild Traumatic Brain ...
-
TecTraum’s pro2cool Receives FDA Designation as a Breakthrough Device for the Treatment of Concussions
TecTraum Inc., dedicated to providing the world’s first point-of-care treatment for concussions, today announced that the U.S. Food and Drug Administration (FDA) has designated its flagship technology, pro2cool, as a Breakthrough Device. The pro2cool System is a novel, non-invasive hypothermic therapy device designed to reduce the severity of concussion symptoms and allow patients to ...
-
TecTraum Announces Completion of Multisite Clinical Trial Using pro2cool Device for the Treatment of Concussions
TecTraum Inc., dedicated to providing the world’s first point-of-care treatment for concussions, announced complete enrollment status for a clinical trial that began in fall of 2019 using its flagship technology, pro2cool. The pro2cool system is a novel, noninvasive hypothermic therapy device designed to reduce the severity of concussion symptoms and allow patients to return to their ...
-
This year`s Medical Innovation Summit will highlight neurosciences innovation
Thousands of researchers, investors, entrepreneurs and those who are simply curious will descend upon the Cleveland Convocation Center October 26-28 for Cleveland Clinic Innovations Medical Innovation Summit. This year’s theme, The Neurosciences: Memory. Mood. Movement, will cover all aspects of the human brain and how it functions and malfunctions. “This is our marquee event,” ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you